News

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage

A coalition is pushing for interoperability advances that it believes could help curb the opioid epidemic. Here’s what it is fighting for.

The landscape of data exchange efficiency continues to be uneven, with some healthcare organizations communicating more proficiently than others. These are the ones struggling the most.

In the year ahead, we can expect to see an insurgence in technology solutions that address patient engagement, data, and security throughout the healthcare system.

John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.

Survey reveals why 2018 will be the year for telemedicine

A new report reveals the top cities that rise to the top for healthcare-and they’re probably not the cities you’d expect.

A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.

Due to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.

A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.

The healthcare landscape is transforming. Here are six considerations to help your talent during restructuring, downsizing, and other transitions.

Make the rules work for, rather than, against you by relying on these five critical capabilities.

Here are three strategies to navigate toward next-generation care management and increase member engagement in the process

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

Successfully separating the signal from the noise, especially in healthcare, can be a tremendous value creator.

Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.

FDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.

FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.

Putting together the right team of data specialists is an important part of the future growth of a healthcare organization. Do you have the right team in place?

Study reveals growing acceptance of value-based payments among family physicians, but barriers still exist.

The benefits and drawbacks of predictive modeling in end-of-life care decision making.

In the next decade, many of the concepts aiming to streamline the healthcare industry could be reality.

Health systems realize that telehealth can help them achieve a wide range of objectives, from care coordination to readmission avoidance and market share expansion.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.

FDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.

A KPMG-Leavitt Partners report shows Medicare Advantage and Managed Medicaid are on slightly different trajectories. Expert Ash Shehata shares his predictions for both markets.